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Abstract
Background: Two or more factor mixed factorial experiments are becoming increasingly
common in microarray data analysis. In this case study, the two factors are presence (Patients with
Alzheimer's disease) or absence (Control) of the disease, and brain regions including olfactory bulb
(OB) or cerebellum (CER). In the design considered in this manuscript, OB and CER are repeated
measurements from the same subject and, hence, are correlated. It is critical to identify sources of
variability in the analysis of oligonucleotide array experiments with repeated measures and
correlations among data points have to be considered. In addition, multiple testing problems are
more complicated in experiments with multi-level treatments or treatment combinations.
Results: In this study we adopted a linear mixed model to analyze oligonucleotide array
experiments with repeated measures. We first construct a generalized F test to select differentially
expressed genes. The Benjamini and Hochberg (BH) procedure of controlling false discovery rate
(FDR) at 5% was applied to the P values of the generalized F test. For those genes with significant
generalized F test, we then categorize them based on whether the interaction terms were
significant or not at the α-level (αnew = 0.0033) determined by the FDR procedure. Since simple
effects may be examined for the genes with significant interaction effect, we adopt the protected
Fisher's least significant difference test (LSD) procedure at the level of αnew to control the familywise error rate (FWER) for each gene examined.
Conclusions: A linear mixed model is appropriate for analysis of oligonucleotide array
experiments with repeated measures. We constructed a generalized F test to select differentially
expressed genes, and then applied a specific sequence of tests to identify factorial effects. This
sequence of tests applied was designed to control for gene based FWER.
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Background
Experiments in which subjects are assigned randomly to
levels of a treatment factor (or treatment combinations of
more than one factor) and then are measured for trends at
several sampling times, spaces or regions (within-subject
factors) are increasingly common in clinical and medical
research. The analysis of interaction, main effects and simple effects are appropriate for analyzing these types of
experiments [1]. Main effects are average effects of a factor,
and interaction effects measure differences between the
effects of one factor at different levels of the other factor.
As an example, this paper studies a 2 × 2 factorial treatment design, in which effects of two factors (treatment
and region, for example) are studied and each factor has
only two levels (with or without certain treatment, two
different regions of studied subjects). The measurements
from different regions of a subject are repeated measures
on the individual and are correlated. In combination with
microarray technology [2], this type of design allows one
to investigate how treatments alter changes in gene expression in time or region simultaneously across a large
number of genes. Two issues are crucial in the analysis of
microarray experiments with repeated measures. Firstly,
sources of variability must be identified, and the correlation structure among within-subject measurements needs
to be taken into account; and secondly, multiple testing is
also an immediate concern if tests of interaction, main
effects, and/or simple effects are performed for each gene.
It has been shown that replication is the key not only to
increasing the precision of estimation but also to estimating errors associated with tests of significance [3]. Previously, a number of ways to identify and model various
sources of errors were proposed for replicated microarray
experiments, and corresponding methods of extracting
differentially expressed genes were suggested [4-8].
Recently, a linear modelling approach [9] and analysis of
microarray experiments using mixed models were also
introduced [10-12], in which the dependency structure of
repeated measurements at the probe level were discussed.
Statistical methods to analyze more complicated experiments, where correlated measurements are taken on one
or more factor levels have not yet been fully described. In
this study, we modified the two-staged linear mixed models [10], and extended them to more complicated designs.
Attention to the multiplicity problem in gene expression
analysis has been increasing. Numerous methods are
available for controlling the family-wise type I error rate
(FWER) [13-17]. Since microarray experiments are frequently exploratory in nature and the sample sizes are
usually small, Benjamini and Hochberg [18]suggested a
potentially more powerful procedure, the false discovery
rate (FDR), to control the proportion of errors among the
identified differentially expressed genes. A number of

http://www.biomedcentral.com/1471-2105/5/209

studies for controlling FDR have followed [17,19-25].
However, these approaches for dealing with the multiplicity problems in microarray experiments are largely
focused on relatively simple one-way layout experimental
designs, and the number of genes that are involved in an
experiment was the major concern. More complicated
designs, such factorial designs with two or more factors,
intensify the multiplicity problem not only because thousands of genes are involved in an experiment, but also
because tests for interactions, main effects, and, possibly,
simple effects need to be performed to further characterize
differences for each gene. It has not been suggested explicitly, however, how to deal with such multiple-testing
problems for two factors (or more than two factors) factorial experiments in the microarray literature.
In this paper, we present a method for analyzing oligonuleotide array experiments with repeated measures
using a linear mixed model, which allows us to model variance-covariance structures associated with such complicated experiments. Our method is also related to that of
Wolfinger et al., 2001, Chu et al., 2002, Kerr et al., 2000,
and Wernisch et al., 2002 [5,9-11]. In addition, we construct a generalized F test to test the null hypothesis that
all the means for all Disease by Region combinations are
equal. Benjamini and Hochberg (BH) procedure of controlling FDR at 5% is used for comparing P values of the
generalized F tests. The test to determine whether the
interaction term is significant is performed only for each
gene with a significant generalized F test. In addition, simple effects are examined for the genes with significant
interaction effect and main effects are tested for those differentially expressed genes which do no exhibit significant
interaction. In the 2 × 2 factorial, this sequence of tests
controls the maximum FWER and, hence the FWER for all
genes. We also illustrate how to summarize and categorize
the interactions using simple diagrams. We demonstrate
our method on the analysis of microarray data from two
regions of the brain, the olfactory bulb (OB) and the cerebellum (CER), from control subjects and patients with
AD. Although a 2 × 2 experiment was used in this manuscript, our methods can be extended to designs with more
than 2 factors or more than 2 levels in one or more factors.
The OB was used because AD patients show pronounced
decrements in their olfactory sensitivity early in the clinical course of the disease [26]. The cerebellum was selected
as a control tissue because it is generally considered to be
minimally affected in AD.

Results
Analysis of gene expression in OB and CER of controls and
AD patients
Based on the statistical methods described (see Methods),
708 genes were considered to be significant by the procedure of controlling FDR at 5% for multiple testing across
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Table 1: Summary of genes with main effects

Main effects
Direction
# of genes
Fold change

Disease
I
32
1.1~2.9

D
17
1.2~2.8

Region
I
331
1.1~104.3

D
228
1.1~121.7

I: significant upregulation of gene expression;
D: significant downregulation of gene expression.

genes. The largest P-value considered to be significant was
0.0033 determined by the FDR procedure. Among the 708
genes, 137 show significant interaction at the level of
0.0033, 49 genes with significant disease effect (32 were
up-regulated and 17 were down-regulated in AD patients)
and 559 genes with significant regional effects (331 were
up-regulated and 228 were down-regulated in the OB)
(Table 1). There were 37 genes that appear on both lists of
significant disease and regional effects (not shown). Further validation studies, such as real time RT-PCR, could be
performed to examine which interpretation is more
reasonable.
A significant interaction effect for a gene has to be
explained so that the gene can be further categorized
based on the nature of the possible alterations of their
expression levels. The interaction patterns were identified
based on the change directions and test results for the following simple effects: control vs AD for OB, control vs AD
for CER, CER vs OB for control, and CER vs OB for AD. The
interaction effects can also be illustrated using simple diagrams by plotting together the average log2 based intensities under control and AD conditions for both OB and
CER. Nonparallel lines in a diagram often imply an interaction effect. An interaction effect can be either directional
or magnitudinal. In this study, directional interactions
refer to the situations when the changes (in gene expression) between AD and control in OB are in the opposite
directions compared to the changes between AD and control in CER. In a magnitudinal interaction, the directions
of the changes between AD and control are the same but
the magnitudes of changes are significantly different. The
gene LOC91614 (UniGene Cluster Hs.180545), which
encodes novel 58.3 kDa protein, is an example with directional interaction effect. As shown in Figure 1 A1, it is significantly up-regulated 2.08 fold in the OBs of AD
patients (Table 2) and significantly down-regulated 3 fold
(1/0.33) in their CERs (Table 2). The function of this gene
is unknown, but, based on the domains identified in its
protein sequence, it is likely to be involved in intracellular
signalling cascades. Given this divergence in the direction
of regulation in these 2 brain regions, this gene would be

of interest for further characterization. The gene encoding
the proteolytic lysosomal enzyme cathepsin H (UniGene
Cluster Hs.114931) has a different pattern of interaction
effects as shown in Figure 1 A2. It was significantly up-regulated 3.51 fold in the OBs of AD patients (Table 2) and
shows a slight non-significant trend toward up-regulation
in their CERs (Table 2). This is consistent with the pronounced activation of lysosomal enzymes that occurs in
regions of the AD brain vulnerable to neurodegeneration
(Nixon et al., 2000), and with the slight increase in lysosomal density in the CER compared with the pronounced
increase in sites of the AD brain with significant neuropathology (prefrontal cortex and hippocampus; [27]). The
patterns for other genes with significant interaction effects
were also determined by the similar method described
above.
In the absence of interaction effects, main effects are often
meaningful. The genes that have either significant main
effect of Disease or Region were also identified and characterized by examining the average difference between AD
and controls or the average difference between OB and
CER. Main effects can also be illustrated by the simple diagrams described above, in which the lines are often parallel. Four genes were used as examples to illustrate main
effect of Disease and main effect of Region (Table 3, Figure
1).
The genes HMGN2 and TSG101 both have significant
effect of Disease (Table 3). HMGN2 (high mobility group
nucleosomal binding protein 2) was significantly downregulated (1.6 fold; p = 0.0009) in the OBs of AD patients
compared to elderly non-demented controls; there was no
significant difference in mean expression levels in the OB
and CER as shown in Figure 1 B1 and B2. Its down-regulation in the OBs of AD patients is consistent with the generally reduced level of gene expression that has been
described in the AD brain [28]. The gene TSG101, was upregulated 1.51 fold (p = 0.0021), with no significant differences in expression levels in the OB and CER. The
encoded protein is a member of the mammalian class E
vps proteins, which mediate ubiquitination-dependent
receptor sorting within the endosomal pathway. The upregulation of TSG101 suggests a potential disruption of
OB neurogenesis.
Two examples of genes with Regional effects are RELN and
B2M (Table 3). RELN is expressed at lower levels in the OB
than in the CER (2.7 fold, p <0.0005) as shown in Figure
1 C1 and C2. The encoded protein is a secreted extracellular matrix molecule that interacts with integrin signalling
to generate a signal for migratory developing neurons to
stop and form layers; thus, a defect in this gene results in
improper development of the cerebellum as well as other
brain regions [29]. B2M, the gene encoding β2 microglob-
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9
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13
12
11
Control
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CER

14

OB

OB

13

CER

Control
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Figurediagrams
Simple
1
to illustrate significant interaction, main effects of Disease and Region
Simple diagrams to illustrate significant interaction, main effects of Disease and Region. The average log transformed intensities under control and AD conditions for both OB and CER were plotted together for each gene with either significant interaction or main effects. The two points from each region were connected using a straight line and the non-parallel
lines imply interaction. Two examples genes with interaction effect were shown in A. A1, represents a directional interaction
and A2 indicates an interaction in magnitude. Two genes with only main effect of disease were illustrated in B, one of which
showed down-regulation in AD (B1), while the other genes were upregulated in AD for both OB and CER. In the bottom
panel, two genes with only regional differences were shown. The gene in C1 has high expression level in CER, and the gene in
C2 has an opposite situation. See also Table 4, 5.
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Table 2: Example of genes with significant interaction effects

Gene

LOC91614
OB

Con

7.02

AD
Overall P
Interaction P
ConOB vs ADOB

ConCER vs ADCER

ConOB vs ConCER

ADOB vs ADCER

Re
fold
dir
Re
fold
dir
Re
fold
dir
Re
fold
dir

Cathepsin H
CER

OB

6.61
6.58
6.78
7.09
6.83
6.74 ± 0.25
6.90 ± 0.17
7.58
7.59
8.21
5.30
5.03
5.58
7.80 ± 0.36
5.30 ± 0.28
0.00058
0.00036
+
2.08
I
+
0.33
D
0.90
N
+
5.66
I

CER

10.53

10.63
10.49
9.46
9.71
9.42
10.55 ± 0.07
9.53 ± 0.16
12.30
12.41
12.37
9.54
9.82
9.79
12.36 ± 0.06
9.72 ± 0.15
2.12e-06
5.86e-06
+
3.51
I
+
1.14
N
+
2.03
I
+
6.23
I

ConOB_ADOB: control vs AD for OB; ConCER_ADCER: control vs AD for CER; ConOB_ConCER: OB vs CER for control subjects;
ADOB_ADCER: OB vs CER for AD patients. Overall P: the P value of the generalized F test. Interaction P: the P value of the interaction term. Re:
the results of the protected Fisher's LSD procedure, where "+" indicates a significant difference and "-" implies a non significant difference ; dir: the
direction of alteration in gene expression levels; D for decrease, I for increase and N for no change in AD when comparing control vs AD, or in OB
when comparing CER vs OB; fold: fold change of each pairwise comparison calculated from the inverse transformed log2 based data. The fold
change of LOC91614 gene expression between AD and control in OB was calculated as: 2(7.58+7.59+8.21)/3/2(7.02+6.61+6.58)/3 = 2.08. The fold changes in
other situations were calculated in a similar way. Similar notations were also used in Table 3. See also Figure 1.

ulin, is expressed at 2.2-fold higher levels in the OB than
in the CER (p < 0.0002). One potential explanation for the
higher levels of B2M expression in the OB than the CER is
that antigens can enter the brain directly along the pathway provided by the axon of the olfactory receptor neuron
or within the sheath of the olfactory nerve; numerous proteins and pathogens enter the brain via this route (e.g.,
[30,31]. The potentially higher level of antigenic stimulation in the OB may result in the up-regulation of B2M
expression, which would not occur in the CER due to the
lack of such a direct connection with the external
environment.
The remaining genes with either significant effects of Disease or Region were also identified and categorized in a
similar way and summarized in Table 1.

have main effect of either Disease or Region. Using simple
diagrams, we can illustrate and further categorize the
interactions and main effects.
This linear mixed model approach allows us to identify
various sources of variability, including experimental
effects, random effects of subjects and random error. The
performance of the generalized F statistic depends on the
validity of the assumed covariance structures and the
degree of replication. We assumed homoscedastic variances for each gene. This may not be true for all genes in
reality. With small sample sizes, which are common in
microarray studies, simpler covariance structures which
require the estimation of fewer variance components are
preferred. Simulation studies showed that, with sample
size of 3, the generalized F test performs reasonably well
in cases with homoscedastic variances.

Discussion
In this study, we adopted a linear mixed model to analyze
oligonuleotide array experiments with repeated measures.
We constructed a generalized F test to select differentially
expressed genes and compared our method to another frequently used approach. Using the method described
above, we identified 708 differentially expressed genes,
137 of which have significant interaction, and 571 genes

We also tested the factorial effects on the 708 genes which
were identified by BH procedure using the more conservative Bonferroni adjustment to the α-level in order to
simultaneously control FDR and the possibility of performing multiple tests for the factorial effects. For example, controlling FDR at 0.05/3 = 1.67%, produced a list of
77 genes. The method we developed is more powerful. In
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Table 3: Example of genes with significant main effects

Gene

Log2 based data
OB
Con

12.68

AD

Overall
P-value
CER

12.73 12.83
12.75 ± 0.08

12.37

12.01

11.94 12.16
12.04 ± 0.11
10.44 10.22 10.26
10.31 ± 0.12

11.53

11.20

11.01 10.96
11.06 ± 0.13
11.49 10.91 10.83
11.08 ± 0.36

10.30

10.59 10.34
10.41 ± 0.16
12.56 12.47 12.62
12.55 ± 0.08

Con

11.33

12.45

RELN
AD
Con

11.00 10.66
11.00 ± 0.34
14.01 14.54 13.89
14.15 ± 0.35

12.35 12.41
12.41 ± 0.06
13.21 13.34 12.74
13.10 ± 0.32

14.03

12.70

B2M
AD

13.84 14.47
14.11 ± 0.32

Main effect of Region

P value

fold

dir

P value

fold

dir

0.0003

0.6462

0.0009*

0.63

D

0.011†

1.24

N

0.0002

0.0726

0.0021*

1.51

I

0.056

1.42

N

0.0025

0.8328

0.5004

0.92

N

0.0005*

0.37

D

0.0011

0.3767

0.5986

0.94

N

0.0002*

2.20

I

12.04 11.81
11.79 ± 0.26
10.09 10.16
9.80
10.02 ± 0.19

TSG101
AD

Main effect of Disease

12.34 12.53
12.41 ± 0.10

HMGN2

Con

Interaction
P-value

12.88 13.06
12.88 ± 0.18

* indicates the P values pass the FDR 5% criteria. † indicates the P values are smaller than 0.05 but larger than the critical value 0.0033 determined
by the FDR procedure. Overall P-value and interaction P-value are the same with the Overall P and Interaction P in Table 4. P values of main effect
of disease and region are the P values of Type III ANOVA test using proc mixed procedure in SAS. Fold of main effect of disease: the ratio of the
average intensities of AD (average over OB and CER) over Control (average over OB and CER). Fold of main effect of region: the ratio of the
average intensities of OB (average over Control and AD) over CER (average over Control and AD). See also Figure 1.

addition, only regional effects were identified without significant interaction and main effect of disease by the alternative method.
In this manuscript, we adopt BH procedure to control
FDR at 5% based on the generalized F tests. Any other
standard multiple testing procedures may also be applied.
A specific sequence of tests was used to identify factorial
effects and control the gene-based FWER in our study. For
researchers who are interested in all pairwise comparisons
among treatment groups, Hayter's modification of the
LSD method [32] controls the FWER for all genes.
We also assumed independence of the significant tests
among genes. This assumption, which is also adopted in
the majority of the microarray literature, may not be completely valid since gene expression is tightly regulated. The
correlation among the genes varies from developmental
stages, tissue to tissue, etc., and we may never be able to
quantify it precisely. The assumption that genes are
correlated in small clusters has been adopted by Benjamini and Yekutieli [21] in their FDR control study. This
assumption, however, has not been completely verified.

Conclusions
A linear mixed model is appropriate for analysis of oligonucleotide array experiments with repeated measures,
allowing us to quantify various sources of error. We constructed a generalized F test to select differentially
expressed genes, and then applied a specific sequence of
tests to identify factorial effects. This sequence of tests
applied was designed to control for gene based FWER.
Our methods can be extended to designs with more than
2 factors or more than 2 levels in one or more factors. The
generalized F test can be constructed for any number of
factors or levels of factors.

Methods
Sources and processing of tissue
OBs were obtained with appropriate informed consent
from patients with Alzheimer's disease (AD) and control
subjects enrolled in the Biologically Resilient Adults in
Neurological Studies (BRAiNS) project of the SandersBrown Center on Aging. At autopsy, OBs and pieces of the
lateral tip of the cerebellums were removed from 6
females, 3 with AD (mean age, 79.0 years; mean postmortem interval 3.8 h) and 3 controls (mean age, 78.6 years;
mean postmortem interval 2.9 h), and immediately
Page 6 of 12
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placed in liquid nitrogen. BRAiNS control subjects had no
clinical evidence of dementia or other neurological problems and scored within the normal range on yearly mental
status tests; on neuropathological examination, their
brains exhibited age-related but not disease-related
changes. AD patients received a diagnosis of probable AD
in the Memory Disorders Clinic; on neuropathological
examination, their brains met multiple criteria for definite
AD and exhibited no indications of complications from
cerebrovascular disease [33].
OBs and cerebellum were homogenized in TRI-Reagent
(Molecular Research, Inc., Cincinnati, OH), and total
RNA was extracted according to the manufacturer's protocol. RNA concentration was determined spectrophotometrically; its integrity and quality were assessed by
spectrophotometry, agarose gel electrophoresis, and Bioanalyzer (Agilent, Technologies, Wilmington, DE) virtual
gels. Following target preparation, the samples were
hybridized onto the Affymetrix Human Genome U133_A
and _B GeneChips at the University of Kentucky Microarray Core Facility according to Affymetrix protocols.
Experimental design
OBs and pieces of the lateral tip of the cerebellums were
previously removed from each of 3 control subjects and 3
patients with AD (all female with similar ages). Total RNA
was extracted from OB and CER tissues for each subject.
Five µg RNA from the OB and CER of each individual were
hybridized with Affymetrix Human Genome U133_A and
_B chips (2 GeneChips/tissue/individual = 24 GeneChips). Data from U133_A and _B chips for each RNA
sample were combined to give 12 data sets with signal
intensities for 44828 targets. Under the assumption of
independence among genes, we have a 2 × 2 factorial
design for each gene with one factor being either control
or AD and with repeated measures (regions, OB or CER)
on each subject. The arrangement for the 2 × 2 mixed factorial design in this experiment is shown as in Table 4,
where µ11, µ12, µ21, and µ22 denotes the average log 2
based expression levels measured in OB of controls, CER
of controls, OB of AD patients and CER of AD patients
respectively. Corresponding measurements from the same
subject are correlated and they are marked as same color.
Our primary interests are to identify various sources of
variability and differentially expressed genes.
Data preparation
Normalization
Background correction and initial total intensity normalization were first performed for the microarray raw data
using Affymetrix Version 5 software [34], resulting in gene
intensities for each gene-chip combination. The log intensities values were used in later processing. We chose the
local regression method (loess) [35-37] to normalize the

http://www.biomedcentral.com/1471-2105/5/209

Table 4: The arrangement for the 2 × 2 factorial design with
repeated measures

Control
AD

OB

CER

µ11
µ21

µ12
µ22

µ11, µ12, µ21, and µ22 are the true means of measurements in OB of
controls, CER of controls, OB of AD patients and CER of AD patients
respectively.

chips within each of the four treatment combinations. The
total intensity method was performed to normalize array
across treatment combinations.
Data Filtering
In our study, all positive control genes and genes that
resulted in an "absent" call for all chips were removed
from further analysis. If there was no evidence that these
genes were expressed in any of the samples, then these
genes can be removed to reduce problems associated with
multiple comparisons. Other methods of removing low
intensity points were also suggested by Bolstad et al., 2003
[37]. All ESTs were also removed from the analysis. Since
the primary interest of these experiments is to identify
known genes that are differentially regulated, eliminating
ESTs will further reduce problems with multiple comparisons. After data filtering steps, 10,590 genes remained,
and the base-2 logarithms of background-corrected and
normalized intensities of these genes were subject to further statistical analyses.
Algorithm and analysis
Analysis of variance components
We use a linear mixed model to describe the experiment.

Let Ygijk be the base-2 logarithm of background-corrected
and normalized intensity of the gth gene, g = 1, ..., 10590,
in the ith Treatment group i = 1, 2, from the jth Region, j
= 1, 2, on the kth subject k = 1, 2, 3. "Treatment" here signifies the health condition of the subjects (controls or AD
patients). A complete linear mixed model for this
experiment:
Ygijk = µ + Di + Sik + Rj + (DR)ij + Aijk + Gg + (GD)gi + (GR)gj
+ (GDR)gij + εgijk, (1)
where µ is the grand mean, Di and Rj and are the main
effects of treatments, regions respectively, and (DR)ij are
the treatment-region interaction effects. Here Sik are the
random effects of subjects within disease group and Aijk
are the random effects of chips. The symbols Gg, (GD)gi,
(GR)gj and (GDR)gij represent the main effect of gene,
gene-treatment interaction effects, gene-region interaction
Page 7 of 12
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effects, gene-treatment-region interaction effects, while
εgijk are the additive stochastic errors
In general, it is impractical, using currently available software, to fit linear models such as (1) with microarray data
involving manipulation of the full covariance matrix of
observation variables that usually contains thousands of
levels. To be conceptually and computationally more efficient, Wolfinger et al., 2001 [10] suggested a two-step
model to separate experimental-wise systematic effects
(normalization sub-model) and the remaining effects for
each gene (gene sub-model). In our case, however, the
design matrix for the fixed effects of Di, Rj and (DR)ij is
orthogonal to the design matrix for the fixed effects
involving each gene, including Gg, (GD)gi, (GR)gj and
(GDR)gij. Therefore, the normalization model has no
effect on the inference for each gene under the assumption in (1). A simpler model can be adopted for each gene,
and the random effect Sik is absorbed by Sgik terms and Aijk
is absorbed by εgijk terms. We make standard stochastic
assumptions that the random effects Sgik, and εgijk are normally distributed with zero means with variances σgs2, and
σg2 respectively. These random effects are assumed to be
independent both across their indices. The model equation then becomes
Ygijk = µg + Dgi + Rgj + (DR)gij + Sgik + εgijk.

(2)

In matrix notation, the model equation for each gene can
be written
Y = Xβ + Zu + ε,

(3)

where Y is a vector of observations, X and Z are matrices
of known constants for the fixed effects and random
effects, respectively, β is a vector containing fixed effect
parameters Dgi, Rgj, and (DR)gij, u is a vector of random
effects, and ε is the error or residual vector. Therefore, Y ~
MVN (Xβ,V) where V = ZDZ' + Σ. The covariance matrices
D = var(u) and Σ = var(ε) can have any valid variance-covariance matrix form. The variances of gene specific subject
effects S can vary for different treatments and different
genes, while ε effects can have different variances for different treatments, regions and different genes. The
remaining terms are fixed effects. All effects and variance
components in the model can be estimated using the
method of restricted maximum likelihood (REML) [38].
In the homogeneous variance case assumed here, since
observations across subjects are independent, the variance-covariance matrix for gene g, Vg, is block diagonal
where
Vg = diag (Σg)

and


 σ g 2 + σ gs2
σ gs2

Σg = 
2
2
 σ 2
σ
σ
+
gs
g
gs 

If the assumption of homoscedasticity is not viable, the
variance-covariance for gene g can easily be accommodated by allowing Σg to vary across disease groups.
Estimation of model parameters
The estimate of primary interest is β, which containing
treatment, region effects and treatment-region interaction
for each gene. For each gene, β is estimated by

βˆ = ( X ′V −1 X)−1 X ′V −1Y .

(4)

The estimated β̂
β has covariance

cov(βˆ ) = ( X ′V −1 X)−1 ,

(5)

where in practice components of V are replaced by their
REML estimates. See Verbeke and Molenberghs (2000) [1]
for methods to derive equations (3)–(5) and REML estimates of the random components in details.
Construct a generalized F test
Genes showing significant interaction effects are defined
as those in which the difference in expression levels
between control and AD is not the same with the difference between OB and CER. Main effects are meaningful in
the absence of interaction effect. Genes showing a significant disease-related effect or main effect of disease are
defined as those either under- or over-expressed by AD
patients compared to controls at the same extent in both
OB and CER, while genes with significant main effect of
region are those either under- or over-expressed in OB
compared to CER at the same extent by both AD and controls. If the expression levels for a gene are the same across
all treatment-region combinations, then there will be neither significant interaction nor main effects; therefore this
gene should be excluded from further analysis. The
expression of other genes may be altered by treatment or/
and region effects, and further analysis of these genes is
needed to characterize the experimental effects. Therefore
the first step to select differentially expressed genes in factorial designs is to choose those for each of which the
hypothesis of equality of all cell means, µ11 = µ12 = µ21 =
µ22, is rejected. Because of the specific variance-covariance
structure for a repeated measures experiment with two levels of the within subject factor, it is convenient to test the
equivalent composite hypothesis for each gene g which is
stated in terms of the main effects and the interaction.
Specifically, we consider
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Table 5: Set up hypothesis using linear contrasts

Ho

L

Effects

Mean

Dg1

Dg2

Rg1

Rg2

(DR)g11

(DR)g12

(DR)g21

(DR)g22

(DR)gij = 0

(µ21 - µ11) (µ22 - µ12) =
0
(µ11 + µ12) (µ21 + µ22)
=0
(µ11 + µ21) (µ12 + µ22)
=0

0

0

0

0

-1

1

1

-1

2

-2

0

0

1

1

-1

-1

0

0

2

-2

1

-1

1

-1

Dgi = 0
Rgj = 0

The hypothesis in terms of model parameters and means were listed. The coefficients for the model parameters of the linear contrasts were
determined for the corresponding hypotheses.

Ho : (DR)gij = 0, i, j = 1, 2 (no interaction)
Dgi = 0,

i = 1, 2

(no main effect of D)

R gj = 0,

j = 1, 2

(no main effect of R).

We can test this composite null hypothesis of no interaction and main effects simultaneously by setting up 3 corresponding linear contrasts listed in Table 5. A contrast is
a linear combination of parameters, for which the coefficients sum to zero [39]. Let L be the 3 × 8 matrix containing the coefficients of the 3 contrasts, then Ho is simplified
as Lβ = 0, where Lβ is estimable, and can be tested using
the generalized F test

F=

(Lβ )′[L( X ′V −1 X)−1 L ′](Lβ )
.
rank (L)

(6)

Under Ho, the generalized F is distributed approximately
as Snedecor's F with degrees of freedom rank(L) and ν
(F[rank(L), ν]). Since the variance-covariance matrix V satisfies a compound symmetry condition, in our example this
statistic is distributed as F[3, 4]. Under other assumptions
of the variance-covariance structures, the denominator
degrees of freedom ν can be approximated by the degrees
of freedom to estimate L(X'V-1 X)-1 L' using Satterthwaite's
procedure [38,40]. Details about how to select appropriate covariance structures were discussed by Littell et al.
(1996) [38] and Keselman et al. (1998) [41].
Adjustment for multiple tests
Multiple testing problems in microarray experiments with
factorial designs are at least two-fold. Usually, hypothesis
tests are performed for each of thousands of genes
involved, and tests of main effects and interactions may
also be needed for each gene. Based on the generalized F

test we constructed above, we now suggest a method for
adjusting multiple tests.
The most commonly used methods to adjust multiple
tests are of controlling either FWER or FDR. These methods are first applied to the P-values from the generalized F
tests, providing a list of genes that exhibit significant difference among the four cell means of Disease by Region
combination. Some of these genes may have significant
interactions, or only the main effects of treatment and/or
region are significant. Further characterizing the significant interactions are one of the major interests for
researchers, and methods for investigate interaction contrasts are available [42-44]. In our study, simple effects
were examined for the genes the have a significant interaction to detect the difference between specific comparisons. Protected by the generalized F test, Fisher's least
significant difference test (LSD) method can be used to
test the necessary simple effects. Here the appropriate
error terms for these simple effects depend on whether the
comparisons involve measurements from same Disease
groups or not. This sequence of tests proposed in this
paper are more powerful, while still allowing for the control of FWER or FDR, compared to directly adjusting P-values using BH procedure with Bonferroni correction. In the
latter method, if we control overall FDR at 5%, we would
perform BH procedure at level of 1.67% or 0.05/3 for each
test of interaction, main effect of disease or region.
Recipe of the analysis
A short summary of the statistical methods used in this
study follows:

1. Linear mixed models were used to describe the data
based on the experimental design and some common
assumptions, and the variance components were
specified.
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4. Using αnew, which equals to the largest P-value considered to be significant in step3 as the cut-off point, we
choose genes with significant interactions (list II) from list
I and, for genes in list II, to test the simple effects. By complete enumerating of all possible combinations of main
effects and interaction effect, one can prove that αnew is an
appropriate choice to control the FWERs while selecting
genes with either significant interaction or main effects in
2 × 2 factorial experiments. From the remaining genes, significant main effects of either disease or region (list III)
were selected. In the example used in this study, αnew =
0.0033.
Statistical software
Data normalization and generation of simulated data
were performed using S-plus version 6.1. We used SAS
(version 9.0) proc mixed procedure to do Model fitting
and significance analysis. The SAS program implementing
linear mixed models for the AD data is available on
request from the first author.
Simulation studies
We constructed a generalized F test to select differentially
expressed genes (see method). To assess the performance
of the constructed generalized F test with small sample
sizes, we performed simulation studies. Since expression
levels of genes in the OB or CER from an individual
(either a control or patient with AD) are considered to be
repeated measures, correlated data should be generated
for the simulations. First, we studied the case (case I) with
equal variance and covariance structure for each individual subject (control or AD patient). We generated 10,000
sets of correlated data; each set has 6 bivariate observations, with mean 20 and the following covariance structure for each subject under either Disease condition (i = 1
for control, and i = 2 for AD; j or j' = 1 for OB, and j or j' =
2 for CER, k = 1, 2, 3):

 1 0.5 
Cov(Ygijk , Ygij′k ) = 
 , j ≠ j′
 0.5 1 
where Ygijk and Ygij'k are measurements from the jth and j'th
levels of Region for the kth subject in the ith level of Disease for gene g. The generalized F-statistics were computed
for each of the 10,000 data sets and the histogram of the

0.5
0.4

Density

3. To adjust the multiple tests for numbers of genes, the
BH method of controlling FDR [18] at 5% was applied to
the P-values obtained above, providing a list of genes (list
I) that exhibit significant differences among the means of
the Disease*Region combinations.
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2. For each gene, a generalized F test was performed based
on the described model, and the corresponding P-value
was obtained.
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Figure 2 of Simulated F statistics
Histograms
Histograms of Simulated F statistics. The histograms of
the F statistics from F[3, 4] (grey in A, B), simulated data with
same covariance structure among individuals (cyan, case I in
A) or unequal variance for subjects from controls and AD
patients (blue, case II in B). Case I has slightly larger tail than
random generated F values, and the right tail of case II were
thicker than both of cases above.

generalized F-statistics was compared with that of randomly generated F values from a F[3, 4] distribution as
shown in figure 2A. The histogram of the generalized Fstatistics has a slightly larger tail. The proportion of the
generalized F-statistics that were no larger than the critical
value, F[3, 4, α = 0.05] = 6.59 was 5.12%, instead of the nominal 5%, 4.97% random generated F values were smaller
than 6.59.
More complicated variance and covariance structure can
also be assumed. For example, the controls and AD
patients may have a different covariance matrix. We then
generated simulated data to study cases like above (case
II). Using the same covariance structure as above, we generate 10,000 sets of data for controls. For AD, we
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generated 10,000 sets of data using a different covariance
structure

14.

2 1
Cov(Yg 2 , Yg 2 ) = 
 , j ≠ j′
jk
j ′k
1 2

16.

Then we computed the generalized F-statistics and compared them with randomly generated F values described
above (Figure 2B). The histogram of the generalized F-statistics has a slightly larger tail than those of both random
generated F values and case II. There was 5.42% of the
generalized F-statistics in case II were larger than the critical value 6.59. With small sample size in both cases (n =
3), the constructed generalized F-statistics behave reasonably well.
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